Aug 14 (Reuters)-
Brightpath Biotherapeutics Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2020 Jun 30, 2019 Mar 31, 2021
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 0 mln 0 mln 3 mln
(-61.2 pct) (-73.5 pct)
Operating loss 408 mln loss 423 mln loss 1.89
Recurring loss 407 mln loss 421 mln loss 1.89
Net loss 409 mln loss 417 mln loss 1.91
EPS loss 9.52 yen loss 9.94 yen loss 45.30 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Brightpath Biotherapeutics Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T